Core Points - The 2025 National Medical Insurance Directory has added 114 new drugs, including 50 innovative drugs, which will significantly enhance patient access to essential medications [1][3][6] - The introduction of the Commercial Health Insurance Innovative Drug Directory marks a pivotal moment for innovative drug accessibility, allowing companies to explore new payment channels beyond traditional insurance [12][13] - The overall number of drugs in the National Medical Insurance Directory has increased to 3,253, with a notable focus on critical areas such as oncology, chronic diseases, and rare diseases [6][11] Group 1: National Medical Insurance Directory - The 2025 National Medical Insurance Directory includes 114 new drugs, with 50 classified as innovative drugs, such as Tislelizumab and domestic ADCs [1][3] - The directory aims to bridge gaps in basic medical insurance coverage for major diseases like triple-negative breast cancer and lung cancer [3][4] - The total number of drugs in the National Medical Insurance Directory has risen to 3,253, enhancing coverage for key disease areas [6] Group 2: Commercial Health Insurance Innovative Drug Directory - The Commercial Health Insurance Innovative Drug Directory includes five CAR-T cell therapies and two Alzheimer's disease drugs, addressing previously limited access due to high costs [1][7] - The directory allows innovative drug companies to seek new payment avenues, enhancing the affordability and accessibility of high-value drugs [12][13] - The introduction of this directory is seen as a significant milestone in improving patient access to innovative therapies [8][9] Group 3: Industry Impact and Future Outlook - The past decade has seen a surge in China's innovative drug development, with the 2025 directory marking a new phase in business development for the industry [11] - The dual-track payment framework of basic insurance and commercial insurance is expected to stimulate the market for innovative drugs [13] - Companies are encouraged to collaborate with insurance providers to enhance patient coverage and awareness of health insurance options [12][13]

每经记者｜金喆 陈星 每经编辑｜贾运可 12月7日，2025创新药高质量发展大会在广州白云国际会议中心召开，1000多人的会场座无虚席。当天 的重要议程之一，是公布《国家基本医疗保险、生育保险和工伤保险药品目录（2025年）》（以下简称 国家医保目录）及首版《商业健康保险创新药品目录（2025年）》（以下简称商保创新药目录）。 《每日经济新闻》记者在现场看到，药明巨诺副总裁樊琳接受了印有"2025商业健康保险创新药目录"字 样的荣誉展示牌，其公司产品"瑞基奥仑赛注射液"名称标注于展示牌下方。对于此次产品纳入商保创新 药目录，樊琳表示，药明巨诺已经等了4年。 记者了解到，2025年国家医保目录成功新增114种药品，其中有50种是一类创新药，包括替尔泊肽、国 产ADC（抗体偶联药物）芦康沙妥珠单抗等明星药物。商保创新药目录则覆盖了5款国产CAR-T（嵌合 抗原受体T细胞免疫疗法）细胞药物、2款进口阿尔茨海默病药物及罕见病药物。 会场中，弥漫着一种超越单个企业捷报的、更具普遍意义的振奋。对于所有新纳入国家医保目录的药品 而言，它们从实验室到患者手中的"最后一公里"将因医保支付的托底而大大提速，医药企业研发投资的 可 ...